The European Medicines Agency (EMA) has answered nine questions on how the revised Brexit rules apply to centrally authorized medicinal products for human use that are sold in Northern Ireland.
Under the original Brexit agreement, EU pharmaceutical law continued to apply in Northern Ireland after the UK left the union, creating challenges for trade and situations in which medicines were approved in one part of the UK but not another. Last year, the European Commission and the UK agreed on changes to fix these problems…
